Hartford Business Journal Special Editions

BOOK OF LISTS 2015-2016 Technology www.HartfordBusiness.com decemBer 28, 2015 • Hartford Business Journal 89 Largest bioscience/biotechnology companies in Connecticut (Ranked by number of employees as of March 2015) Rank Company Headquarters No. of employees in CT No. of R&D employees in CT Focus Year founded Chief executive 1 Pfizer Inc. 558 Eastern Point Road Groton, CT 06340 860-441-4100; www.pfizer.com New York, NY 3,000 DND Medicinal chemistry, pharmacokinetics, dynamics and metabolism, pharmaceutical sciences, clinical trials, drug safety, comparative medicine, regulatory 1849 Ian C. Read Chairman & CEO 2 Boehringer Ingelheim Pharmaceuticals Inc. 900 Ridgebury Road Ridgefield, CT 06877 800-344-3095; us.boehringer-ingelheim.com Ridgefield, CT 2,700 DND Development and manufacture of human and animal healthcare products 1885 Paul R. Fonteyne President & CEO, Boehringer Ingelheim USA 3 Bristol-Myers Squibb Co. 5 Research Pkwy. Wallingford, CT 06492 (1) 203-677-6000; www.bms.com New York, NY 925 DND Drug discovery and drug development activities within the following concentrations: applied biotechnology, applied genomics, chemistry, clinical research, metabolism and pharmacokinetics, neuroscience, virology 1858 Giovanni Caforio CEO 4 Alexion Pharmaceuticals Inc. 352 Knotter Dr. Cheshire, CT 06410 203-272-2596; www.alxn.com Cheshire, CT 750 210 Severe and life-threatening rare disorders 1992 David L. Hallal CEO 5 PerkinElmer Inc. 710 Bridgeport Ave. Shelton, CT 06484 (2) 203-925-4600; www.perkinelmer.com Waltham, MA 500 DND Human and environmental health 1937 Robert F. Friel Chairman & CEO 5 Purdue Pharma LP 1 Stamford Forum, 201 Tresser Blvd. Stamford, CT 06901 800-745-7445; www.purduepharma.com Stamford, CT 500 110 Prescription and non-prescription medicines and hospital products; development of opioid pain medications with abuse-deterrent properties 1991 Mark Timney President & CEO 7 MannKind Corp. 1 Casper St. Danbury, CT 06810 203-798-8000; www.mannkindcorp.com Valencia, CA 221 34 Inhalation product technologies 1991 Hakan Edstrom President, CEO & director 8 Protein Sciences Corp. 1000 Research Pkwy. Meriden, CT 06450 800-488-7099; www.proteinsciences.com Meriden, CT 140 DND Vaccine development and protein production 1983 Manon M. J. Cox President & CEO 9 The Jackson Laboratory for Genomic Medicine (3) 10 Discovery Dr. Farmington, CT 06032 860-837-2474; www.jax.org Bar Harbor, ME 130 DND Genomic causes of and treatments for diseases 2014 (4) Edison T. Liu President & CEO 10 Achillion Pharmaceuticals 300 George St. New Haven, CT 06511 203-624-7000; www.achillion.com New Haven, CT 62 50 Infectious disease and complement-related diseases 1998 Milind S. Deshpande President & CEO 11 Transgenomic Inc. 5 Science Park New Haven, CT 06511 203-907-2201; www.transgenomic.com Omaha, NE 55 3 Genetic testing 1997 Paul Kinnon President & CEO 12 Kolltan Pharmaceuticals Inc. 300 George St., Ste. 530 New Haven, CT 06511 203-773-3000; www.kolltan.com New Haven, CT 39 27 Receptor tyrosine kinases 2007 Gerald McMahon President & CEO 13 Biodel Inc. 100 Saw Mill Rd. Danbury, CT 06810 203-796-5000; www.biodel.com Danbury, CT 35 17 Therapeutics for endocrine disorders 2003 Errol De Souza President & CEO 14 Melinta Therapeutics Inc. 300 George St., Ste. 301 New Haven, CT 06511 203-624-5606; www.melinta.com New Haven, CT 34 29 Discovery, development and commercialization of antibiotics to overcome resistant, life-threatening infections DND Eugene Sun Interim CEO & EVP, Research & Development 15 Gilead Connecticut Inc. 36 E. Industrial Road Branford, CT 06405 203-315-1222; www.gilead.com Foster City, CA 30 26 HIV/AIDS, liver diseases, cancer and inflammation, respiratory and cardiovascular conditions 1987 John C. Martin Chairman & CEO 16 Ce3 Inc. 246 Goose Lane, Ste. 202 Guilford, CT 06437 203-404-7500; www.ce3inc.com Guilford, CT 25 DND Contract research focused on providing biotechnology companies with Phase 1 – 2 clinical trial execution and regulatory submission services 2005 Holly Ohanesian Coulter President & CEO 17 Arvinas Inc. 5 Science Park, 395 Winchester Ave. New Haven, CT 06511 203-535-1456; www.arvinas.com New Haven, CT 22 20 Development of novel therapeutics to treat a variety of diseases including cancer, pro-inflammatory, autoimmune and rare disease 2013 Manuel Litchman President & CEO 17 AxioMx Inc. (5) 688 E. Main St. Branford, CT 06405 203-208-1918; www.axiomxinc.com Branford, CT 22 9 Recombinant antibody technology development 2012 Christopher McLeod President & CEO 19 NanoViricides Inc. 1 Controls Dr. Shelton, CT 06484 203-937-6137; www.nanoviricides.com Shelton, CT 20 15 Nanotechnology-based biomimetic anti-viral medicines targeting influenzas, bird flu, HIV/AIDS, cold sores, genital herpes infection, viral eye diseases, ebola, dengue viruses 2005 Eugene Seymour CEO 20 CARA Therapeutics 1 Parrott Dr. Shelton, CT 06484 203-567-1500; www.caratherapeutics.com Shelton, CT 16 7 Development of novel therapeutics to treat human diseases associated with pain, inflammation and pruritus 2004 Derek Chalmers Director, president & CEO Source: CURE, each company via survey. Notes: R&D = research and development, DND = did not disclose. While Becton Dickinson and Idexx Laboratories Inc. have R&D operations outside of Connecticut, local facilities are dedicated to manufacturing and thus omitted from this list. Charles River Laboratories International Inc., CooperSurgical Inc., Icahn School of Medicine Mount Sinai Genomics Research Center and Medtronic Inc. (which acquired Covidien PLC) were contacted but did not complete survey. Hologic Inc. has both manufacturing and R&D operations in Danbury, however the company does not disclose employee data by geographic location. Spinifex Pharmaceuticals, which appeared on this list in March 2015, was acquired by Novartis in June 2015; it is not included here as continued presence in Connecticut could not be confirmed. (1) In early 2018, BMS plans to close Wallingford site and move 900-plus employees to other locations in Connecticut and Cambridge, Mass. (2) With an additional R&D operation in Branford. (3) On the campus of University of Connecticut Health Center. (4) Year founded for this site; The Jackson Laboratory, headquartered in Maine, was founded in 1929. (5) Acquired by Abcam plc, based in the United Kingdom, in Dec. 2015. —Compiled by Roger Magnus and Heide Martin.

• Cover